$CODX

Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER T

Co-Diagnostics said it completed a proof-of-concept for an extraction-free Ebola test using its Co-Primers technology on the Co-Dx PCR Pro with diluted plasma. The work followed a C-CAMP request for 200 kits. The company is running analytical studies for Bundibugyo kits and developing a second-generation pan-Ebola assay. Shares rose 6.86% to $2.18 premarket.

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001692415 0001692415 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Co-Diagnostics said it has begun clinical studies in India for its PCR Pro TB test platform, following shipments of PCR Pro instruments, MTB test kits, and sample preparation instruments to CoSara. The decentralized PCR platform is designed to return results in about 30 minutes. CoSara is deploying the CoSara-branded instrument in select labs. Co-Diagnostics shares were up 1.69% to $2.40 premarket.

Co-Diagnostics (NASDAQ:CODX) said it completed clinical and analytical performance studies for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument. The company plans to include the results in its FDA submission package for a Dual 510(k) and CLIA Waiver by Application targeted for Q3 2026. Shares were down 0.65% premarket to $3.08.

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Egan Dwight H (Chief Executive Officer) sold (to issuer) 1,633 shares of Co-Diagnostics, Inc. (CODX) at $5.07 on 2026-05-23.

Brown Brian Lee (Chief Financial Officer) sold (to issuer) 1,350 shares of Co-Diagnostics, Inc. (CODX) at $5.07 on 2026-05-23.

Co-Diagnostics, Inc. (NASDAQ:CODX) will effect a 1-for-30 reverse stock split on January 2, 2026, to meet Nasdaq's minimum bid price requirement. The company's stock has plummeted 69.44% year-to-date, and it reported significant revenue decline in Q3 2025. Despite financial challenges, Co-Diagnostics continues to expand its technology, recently securing an Australian patent for its Co-Dx PCR Pro platform and receiving a "Buy" rating from Maxim Group.